Differential characteristics of endogenous serotonin-mediated synaptic transmission in the hippocampal CA1 and CA3 fields of anaesthetized rats. 2002

Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
Department of Pharmacology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan. mbird@med.hokudai.ac.jp

The characteristics of endogenous serotonin (5-HT)-mediated synaptic transmission were investigated in the hippocampal CA1 and CA3 fields of anaesthetized rats. Electrophysiological approaches were used to elucidate the effects of a selective 5-HT reuptake inhibitor, fluvoxamine, on synaptic transmission by determining the population spike amplitude (PSA). Fluvoxamine (10 or 30 mg/kg i.p.) increased the PSA in the CA1 and CA3 fields concentration dependently, whereby this facilitatory response was greater in the CA3 than in the CA1 field. Fluvoxamine (30 mg/kg i.p.)-induced increases in the PSA were augmented by the 5-HT(1A) receptor antagonist NAN 190 (0.5 mg/kg i.p.) and prevented by the 5-HT(4) receptor antagonist GR 113808 (20 micro g/rat i.c.v.) or by the 5-HT(7) receptor antagonist DR 4004 (10 micro g/rat i.c.v.) in the CA1 field. Thus, fluvoxamine-induced facilitatory effects appear to be mediated via 5-HT(1A) and 5-HT(4)/5-HT(7) receptors in an inhibitory and a stimulatory manner, respectively. In the CA3 field, excitability produced by fluvoxamine was abolished by either NAN 190 or DR 4004, but not by GR 113808, suggesting that 5-HT(1A) and 5-HT(7) receptors contribute to this facilitation. These findings were supported in part by the results obtained by exogenously applied 5-HT receptor agonists: the 5-HT(1A) receptor agonist tandospirone (10 mg/kg i.p.) decreased PSA in the CA1 field, whereas the 5-HT(4) receptor agonist SC 53116 (10 micro g/rat i.c.v.) increased it. In contrast, in the CA3 field, tandospirone increased PSA, whereas SC 53116 had no effect. Taken together, the present study revealed that characteristics of synaptic transmission mediated via 5-HT receptors differ between the CA1 and CA3 fields: in the CA1 field, three 5-HT receptors, 5-HT(1A), 5-HT(4) and 5-HT(7), are associated with the endogenous 5-HT-induced facilitation in an opposite and independent manner. In the CA3 field, at least two 5-HT receptors, i.e. 5-HT(1A) and 5-HT(7), are involved in this mediation in a facilitatory manner. 5-HT neurons may modulate pyramidal neuron responses to incoming stimuli by complex mechanisms involving these 5-HT receptors. In other words, the net effects resulting from the differential characteristics in the CA1 and CA3 fields may play an important role in the physiological functions of the hippocampus.

UI MeSH Term Description Entries
D008297 Male Males
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000200 Action Potentials Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli. Spike Potentials,Nerve Impulses,Action Potential,Impulse, Nerve,Impulses, Nerve,Nerve Impulse,Potential, Action,Potential, Spike,Potentials, Action,Potentials, Spike,Spike Potential
D000777 Anesthetics Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. Anesthetic,Anesthetic Agents,Anesthetic Drugs,Anesthetic Effect,Anesthetic Effects,Agents, Anesthetic,Drugs, Anesthetic,Effect, Anesthetic,Effects, Anesthetic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
February 2015, Journal of neural transmission (Vienna, Austria : 1996),
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
October 2013, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
March 1985, Neuroscience,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
February 2005, Journal of neurophysiology,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
May 1998, Toxicology letters,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
December 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
September 1996, Brain research,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
February 2021, International journal of molecular sciences,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
April 2022, Acta neuropathologica communications,
Machiko Matsumoto, and Taku Kojima, and Hiroko Togashi, and Kiyoshi Mori, and Satoshi Ohashi, and Ken-ichi Ueno, and Mitsuhiro Yoshioka
March 2018, Hippocampus,
Copied contents to your clipboard!